LakePharma Announces Antibody Collaboration & License Agreement - Erie News Now | WICU & WSEE in Erie, PA

LakePharma Announces Antibody Collaboration & License Agreement with XOMA

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE LakePharma

BELMONT, Calif., Oct. 4, 2017 /PRNewswire/ -- LakePharma, the leading US-based biologics company offering integrated solutions for biologics discovery, development and manufacturing, today announced a non-exclusive license agreement with XOMA to use XOMA's 031 Fab Phage Display Library in its antibody discovery service to pharma and therapeutic biotech companies.

LakePharma is a leading US-based contract research organization (CRO) specializing in antibody and protein engineering, cell line development, and protein production.

XOMA 031 is a naïve human Fab phage display library with more than 300 billion clones covering the human antibody repertoire. Due to the high sequence diversity of target-specific antibody binders derived from this phage library, high affinity clones can be discovered for many targets.  XOMA and its partners have used this library to discover several antibodies that are currently in the clinic.

Aaron Sato, Ph. D., Chief Scientific Officer of LakePharma, said: "The XOMA phage display libraries have yielded many developable, low immunogenicity, and highly potent antibody drug candidates that are currently in the clinic.  For these reasons, their library is validated to produce clinical candidates.  We are so excited to be able to offer XOMA 031 Fab library discovery projects to our clients." 

About LakePharma

LakePharma is the leading US-based biologics company specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, and bioanalytics.  LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal. For more information, please visit

Aaron Sato, Ph.D.
Chief Scientific Officer, LakePharma

About XOMA

XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company's pioneering efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. For more information, please visit


View original content with multimedia:

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly
3514 State St. Erie, PA 16508
Newsroom: (814) 454-8812
Business offices: (814) 454-5201
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
RSS Feeds
All content © Copyright 2000 - 2017 WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 -